A virtual collaborative care model enhances mental health support in oncology, improving patient outcomes and addressing care disparities in underserved populations.
Experts discuss a virtual collaborative care model that integrates mental health support into oncology, enhancing patient care and improving treatment outcomes.
Experts explore a virtual collaborative care model to enhance mental health support for breast cancer patients, aiming to improve treatment adherence and outcomes.
The HER2CLIMB-05 trial reveals tucatinib enhances progression-free survival in HER2-positive metastatic breast cancer, offering new hope for patients.
Join Dr Krish Patel and discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results.
ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.
Tucatinib enhances frontline maintenance therapy for HER2-positive metastatic breast cancer, significantly improving progression-free survival compared to placebo.
Bradley Monk, MD, highlights transformative long-term outcomes from the innovaTV trial, showcasing innovative treatments for cervical cancer at ESMO 2025.
Discover groundbreaking advancements in breast cancer treatment, focusing on targeted therapies, immunotherapy, and personalized care strategies for improved patient outcomes.
Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.
Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.
Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.
Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.
During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.
Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential in targeted therapy advancements.
Emiltatug ledadotin demonstrated promising antitumor activity and a manageable safety profile in a phase 1 dose-escalation trial.
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.
David Spigel, MD, discusses the pivotal findings from the AIM-HIGH trial in early-stage non-squamous NSCLC.
Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.
During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.
Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.
Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.
David Andorsky, MD, discusses efficacy and safety findings from the ASC2ESCALATE study of asciminib in chronic myeloid leukemia.
David Andorsky, MD, discusses the dose escalation design of the ASC2ESCALATE study exploring asciminib's role in chronic myeloid leukemia.
Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.
Deepak Bhamidipati, MD, discusses the impact of the FDA's Project Optimus on early-phase drug development protocols.
During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.
David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.